259 related articles for article (PubMed ID: 20203507)
1. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Fronzoni L; Serra M; Corinaldesi R
Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
[TBL] [Abstract][Full Text] [Related]
2. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
[TBL] [Abstract][Full Text] [Related]
3. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
[TBL] [Abstract][Full Text] [Related]
4. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
Andrews CN; Griffiths TA; Kaufman J; Vergnolle N; Surette MG; Rioux KP
Aliment Pharmacol Ther; 2011 Aug; 34(3):374-83. PubMed ID: 21671966
[TBL] [Abstract][Full Text] [Related]
5. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
Barbara G
Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.
Cremon C; Gargano L; Morselli-Labate AM; Santini D; Cogliandro RF; De Giorgio R; Stanghellini V; Corinaldesi R; Barbara G
Am J Gastroenterol; 2009 Feb; 104(2):392-400. PubMed ID: 19174797
[TBL] [Abstract][Full Text] [Related]
7. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?
Crentsil V
Med Hypotheses; 2005; 65(1):97-102. PubMed ID: 15893125
[TBL] [Abstract][Full Text] [Related]
8. The putative role of the intestinal microbiota in the irritable bowel syndrome.
Collins SM; Denou E; Verdu EF; Bercik P
Dig Liver Dis; 2009 Dec; 41(12):850-3. PubMed ID: 19740713
[TBL] [Abstract][Full Text] [Related]
9. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.
Barbara G; Wang B; Stanghellini V; de Giorgio R; Cremon C; Di Nardo G; Trevisani M; Campi B; Geppetti P; Tonini M; Bunnett NW; Grundy D; Corinaldesi R
Gastroenterology; 2007 Jan; 132(1):26-37. PubMed ID: 17241857
[TBL] [Abstract][Full Text] [Related]
10. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
[TBL] [Abstract][Full Text] [Related]
11. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress.
Vicario M; Guilarte M; Alonso C; Yang P; Martínez C; Ramos L; Lobo B; González A; Guilà M; Pigrau M; Saperas E; Azpiroz F; Santos J
Brain Behav Immun; 2010 Oct; 24(7):1166-75. PubMed ID: 20600818
[TBL] [Abstract][Full Text] [Related]
12. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?
Braak B; Klooker TK; Wouters MM; Welting O; van der Loos CM; Stanisor OI; van Diest S; van den Wijngaard RM; Boeckxstaens GE
Am J Gastroenterol; 2012 May; 107(5):715-26. PubMed ID: 22488080
[TBL] [Abstract][Full Text] [Related]
13. Inflammation and microflora.
Pimentel M; Chang C
Gastroenterol Clin North Am; 2011 Mar; 40(1):69-85. PubMed ID: 21333901
[TBL] [Abstract][Full Text] [Related]
14. T-cell activation in patients with irritable bowel syndrome.
Ohman L; Isaksson S; Lindmark AC; Posserud I; Stotzer PO; Strid H; Sjövall H; Simrén M
Am J Gastroenterol; 2009 May; 104(5):1205-12. PubMed ID: 19367268
[TBL] [Abstract][Full Text] [Related]
15. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.
Matricon J; Meleine M; Gelot A; Piche T; Dapoigny M; Muller E; Ardid D
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1009-31. PubMed ID: 23066886
[TBL] [Abstract][Full Text] [Related]
16. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
17. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome.
Rijnierse A; Nijkamp FP; Kraneveld AD
Pharmacol Ther; 2007 Nov; 116(2):207-35. PubMed ID: 17719089
[TBL] [Abstract][Full Text] [Related]
18. Overlap between irritable bowel syndrome and inflammatory bowel disease.
Spiller RC
Dig Dis; 2009; 27 Suppl 1():48-54. PubMed ID: 20203497
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Can gluten contribute to irritable bowel syndrome?
Verdu EF
Am J Gastroenterol; 2011 Mar; 106(3):516-8. PubMed ID: 21378766
[TBL] [Abstract][Full Text] [Related]
20. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.
Park JH; Rhee PL; Kim HS; Lee JH; Kim YH; Kim JJ; Rhee JC
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):71-8. PubMed ID: 16706815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
